

ELISA Kit Catalog #KHO0431

1

FAK (Total)

www.invitrogen.com

Invitrogen Corporation 542 Flynn Road, Camarillo, CA 93012 Tel: 800-955-6288 E-mail: <u>techsupport@invitrogen.com</u>

TABLE OF CONTENTS

| Introduction | 4 |
|--|----|
| Principle of the Method | 6 |
| Reagents Provided | 7 |
| Supplies Required But Not Provided | 8 |
| Procedural Notes/Lab Quality Control | 8 |
| Safety | 10 |
| Directions for Washing | 10 |
| Procedure for Extraction of Proteins from Cells | 11 |
| Reagent Preparation and Storage | 13 |
| Reconstitution and Dilution of FAK (Total) Standard | 13 |
| Dilution of FAK (Total) Standard | 14 |
| Storage and Final Dilution of Anti-Rabbit IgG HRP (100X) | 15 |
| Dilution of Wash Buffer | 16 |
| Assay Method | 16 |
| Typical Data | 19 |
| Limitations of the Procedure | 20 |
| Performance Characteristics | 21 |
| Sensitivity | 21 |
| Precision | 22 |
| Recovery | 23 |
| High Dose Hook Effect | 23 |
| Parallelism | 23 |
| Linearity of Dilution | 24 |
| Specificity | 24 |
| References | 27 |

INTRODUCTION

Focal Adhesion Kinase (FAK), also known as pp125FAK and FADK 1 (EC,2.7.1.112) is a non-receptor protein tyrosine kinase that localizes to focal adhesions. FAK appears to be ubiquitously expressed among all mammalian tissues, with highest expression levels observed in brain tissue. FAK plays a central role in cell spreading, differentiation, migration, cell death and acceleration of the G1 to S phase transition of the cell cycle.

FAK's amino-terminus, which bears homology with the band 4.1 family of proteins, plays a role in mediating interaction with the cell membrane, the cytoskeleton, and integrin proteins. FAK's carboxyl-terminus, which contains the focal adhesion targeting (FAT) domain, mediates interaction with focal adhesion associated proteins, including talin and paxillin.

FAK is activated by phosphorylation events in response to several stimuli. These stimuli include integrin clustering induced by cell adhesion or antibody cross-linking, G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or by LDL receptor occupancy.

In response to integrin engagement, FAK is autophosphorylated at tyrosine residue 397. This autophosphorylation event creates high affinity binding sites for the SH2 domains of several important signaling proteins, including Src family members (c-Src and Fyn, which are recruited to sites of adhesion and subsequently activated), phosphatidylinositol-3-kinase, phospholipase-C γ and Shc. In addition to tyrosine 397, five other tyrosine residues are phosphorylated in response, including tyrosine residues 407, 576, 577, 861, and 925.

Studies performed suggest that c-Src is the activity that catalyzes the phosphorylation of these residues. Phosphorylation of tyrosine 925, an event which creates a binding site for the Grb2 SH2 domain, contributes to integrin-sitmulated activation of the Ras-ERK2 mitogen-activated protein kinase pathway. FAK promoted phosphorylation of these substrates and subsequent recruitment of Crk are critical downstream signaling events of FAK.

The Invitrogen FAK (Total) ELISA is designed to detect and quantify the level of FAK protein, independent of its phosphorylation state. This assay is intended for the detection of FAK from lysates of human, mouse, and rat cells. This kit can be used to normalize the phosphorylated FAK content of the samples when using the Invitrogen FAK [pY397] ELISA kit (Cat. # KHO0441).

For Research Use Only. CAUTION: Not for human or animal therapeutic or diagnostic use.

Read entire protocol before use

PRINCIPLE OF THE METHOD

The Invitrogen FAK (Total) kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). A monoclonal antibody specific for FAK (regardless of phosphorylation state) has been coated onto the wells of the microtiter strips provided. Samples, including a standard containing FAK (Total), control specimens, and unknowns, are pipetted into these wells. During the first incubation, the FAK (Total) antigen binds simultaneously to the immobilized (capture) antibody and to the solution phase rabbit polyclonal (detection) antibody specific for FAK. After washing, a horseradish peroxidase-labeled Anti-Rabbit IgG (Anti-Rabbit IgG HRP) is added. This binds to the detection antibody to complete the four-member sandwich. After the second incubation and washing to remove the excess Anti-Rabbit IgG HRP, a substrate solution is added, which is acted upon by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of FAK (Total) present in the original specimen.

REAGENTS PROVIDED

Note: *Store all reagents at 2 to 8°C.*

| | <i>96</i> | |
|---|-----------|--|
| Reagent | Test Kit | |
| <i>FAK (Total) Standard</i> : Contains 0.1% sodium azide. Refer to vial label for quantity and reconstitution volume. | 2 vials | |
| | | |
| <i>Standard Diluent Buffer.</i> Contains 0.1% sodium azide; 25 mL per bottle. | 1 bottle | |
| Antibody Coated Wells. 12 x 8 Well Strips. | 1 plate | |
| <i>FAK (Total) Detection Antibody.</i> Contains 0.1% sodium azide; blue dye*; 6.0 mL per bottle. | 1 bottle | |
| <i>Anti-Rabbit IgG HRP (100X).</i> Contains 3.3 mM thymol; 0.125 mL per vial. | 1 vial | |
| HRP Diluent. Contains 3.3 mM thymol; 25 mL per bottle. | 1 bottle | |
| Wash Buffer Concentrate (25X). 100 mL per bottle. | 1 bottle | |
| Stabilized Chromogen, Tetramethylbenzidine (TMB). 25 mL per bottle. | 1 bottle | |
| Stop Solution. 25 mL per bottle. | 1 bottle | |
| Plate Covers, adhesive strips. | 3 | |
| * In order to help our customers avoid any mistakes in pipetting the ELISAs, we provide colored <i>Standard Diluent Buffer</i> , <i>Detection Antibody</i> , and <i>HRP</i> to help monitor the addition of solution to the reaction well. This does not in any way interfere with the test results. | | |

Disposal Note: This kit contains materials with small quantities of sodium azide. Sodium azide reacts with lead and copper plumbing to form explosive metal azides. Upon disposal, flush drains with a large volume of water to prevent azide accumulation. Avoid ingestion and contact with eyes, skin and mucous membranes. In case of contact, rinse affected area with plenty of water. Observe all federal, state and local regulations for disposal.

SUPPLIES REQUIRED BUT NOT PROVIDED

- 1. Microtiter plate reader capable of measurement at or near 450 nm.
- Calibrated adjustable precision pipettes, preferably with disposable plastic tips. (A manifold multi-channel pipette is desirable for large assays.)
- 3. Cell Extraction Buffer (see Recommended Formulation, p. 11).
- 4. Distilled or deionized water.
- 5. Plate washer: automated or manual (squirt bottle, manifold dispenser, etc.).
- 6. Data analysis and graphing software. Graph paper: linear (Cartesian), log-log, or semi-log, as desired.
- 7. Glass or plastic tubes for diluting and aliquoting standard.
- 8. Absorbent paper towels.
- 9. Calibrated beakers and graduated cylinders in various sizes.

PROCEDURAL NOTES/LAB QUALITY CONTROL

- 1. When not in use, kit components should be refrigerated. All reagents should be warmed to room temperature before use.
- 2. Microtiter plates should be allowed to come to room temperature before opening the foil bags. Once the desired number of strips has been removed, immediately reseal the bag and store at 2 to 8°C to maintain plate integrity.

- 3. Samples should be frozen if not analyzed shortly after collection. Avoid multiple freeze-thaw cycles of frozen samples. Thaw completely and mix well prior to analysis.
- 4. If particulate matter is present, centrifuge or filter prior to analysis.
- 5. All standards, controls and samples should be run in duplicate.
- 6. Samples that are greater than the highest standard point should be diluted with *Standard Diluent Buffer* and retested.
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This ensures equal incubation times for all wells.
- 8. Cover or cap all reagents when not in use.
- 9. Do not mix or interchange different reagent lots from various kit lots.
- 10. Do not use reagents after the kit expiration date.
- 11. Read absorbances within 2 hours of assay completion.
- 12. In-house controls should be run with every assay. If control values fall outside pre-established ranges, the accuracy of the assay is suspect.
- 13. All residual wash liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. *Never* insert absorbent paper directly into the wells.
- 14. Because *Stabilized Chromogen* is light sensitive, avoid prolonged exposure to light. Also avoid contact between *Stabilized Chromogen* and metal, or color may develop.

SAFETY

All blood components and biological materials should be handled as potentially hazardous. Follow universal precautions as established by the Centers for Disease Control and Prevention and by the Occupational Safety and Health Administration when handling and disposing of infectious agents.

DIRECTIONS FOR WASHING

Incomplete washing will adversely affect the test outcome. All washing must be performed with *Wash Buffer Concentrate (25X)* provided.

Washing can be performed manually as follows: completely aspirate the liquid from all wells by gently lowering an aspiration tip (aspiration device) into the bottom of each well. Take care not to scratch the inside of the well.

After aspiration, fill the wells with at least 0.4 mL of diluted wash solution. Let soak for 15 to 30 seconds, then aspirate the liquid. Repeat as directed under **ASSAY METHOD**. After the washing procedure, the plate is inverted and tapped dry on absorbent tissue.

Alternatively, the wash solution may be put into a squirt bottle. If a squirt bottle is used, flood the plate with wash buffer, completely filling all wells. After the washing procedure, the plate is inverted and tapped dry on absorbent tissue.

If using an automated washer, the operating instructions for washing equipment should be carefully followed. If your automated washer allows, 30 second soak cycles should be programmed into the wash cycle.

PROCEDURE FOR EXTRACTION OF PROTEINS FROM CELLS

A. Recommended Formulation of Cell Extraction Buffer:

10 mM Tris, pH 7.4
100 mM NaCl
1 mM EDTA
1 mM EGTA
1 mM NaF
20 mM Na₄P₂O₇
2 mM Na₃VO₄
1% Triton X-100
10% glycerol
0.1% SDS
0.5% deoxycholate
1 mM PMSF (stock is 0.3 M in DMSO)
Protease inhibitor cocktail (e.g., Sigma Cat. # P-2714; reconstituted according to manufacturer's guideline). Add 500 µL per 5 mL Cell Extraction Buffer.

This buffer is stable for 2 to 3 weeks at 4°C or for up to 6 months when aliquoted (without protease inhibitors and PMSF added) and stored at -20°C. When stored frozen, the Cell Extraction Buffer should be thawed on ice. This buffer (minus protease inhibitor cocktail and PMSF) can be obtained from Invitrogen Cat. # FNN0011. **Important:** add the protease inhibitors just before using. The stability of protease inhibitor supplemented Cell Extraction Buffer is 24 hours at 4°C. PMSF is very unstable and must be added prior to use, even if added previously.

B. Protocol for Cell Extraction

This protocol has been successfully applied to several cell lines. Researchers should optimize the cell extraction procedures for their own applications.

- 1. Collect cells in PBS by centrifugation (non-adherent) or scraping from culture flasks (adherent).
- 2. Wash cells twice with cold PBS.
- Remove and discard the supernatant and collect the cell pellet. (At this point the cell pellet can be frozen at -80°C and lysed at a later date).
- 4. Lyse the cell pellet in Cell Extraction Buffer for 30 minutes, on ice, with vortexing at 10 minute intervals. The volume of Cell Extraction Buffer depends on the cell number in cell pellet and expression of FAK. For example, 4 x 10⁶ 3T3L1 cells grown in DMEM plus 10% FBS can be extracted in 1 mL of Extraction Buffer. Under these conditions, use of 1-10 μL of the clarified cell extract diluted to a volume of 50 μL/well in *Standard Diluent Buffer* (See Assay Method) is sufficient for the detection of FAK.
- 5. Transfer extract to microcentrifuge tubes and centrifuge at 13,000 rpm for 10 minutes at 4°C.
- 6. Aliquot the clear lysate to clean microfuge tubes. These samples are ready for assay. Lysates can be stored at -80°C. Avoid multiple freeze/thaw cycles.

REAGENT PREPARATION AND STORAGE

A. Reconstitution and Dilution of FAK (Total) Standard

Note: This *FAK (Total) Standard* is prepared using purified, full length, recombinant FAK protein expressed in *Sf*21 cells.

- 1. Reconstitute *FAK (Total) Standard* with *Standard Diluent Buffer*. Refer to standard vial label for instructions. Swirl or mix gently and allow to sit for 10 minutes to ensure complete reconstitution. Label as 100 ng/mL FAK. Use the standard within 1 hour of reconstitution.
- 2. Add 0.15 mL of *Standard Diluent Buffer* to each of 6 tubes labeled 50, 25, 12.5, 6.25, 3.12 and 1.6 ng/mL FAK.
- 3. Make serial dilutions of the standard as described in the following dilution table. Mix thoroughly between steps.

| Standard: | Add: | Into: |
|------------|-----------------------------------|----------------------------------|
| 100 ng/mL | Prepare as described in step 1 | |
| 50 ng/mL | 0.15 mL of the 100 ng/mL std. | 0.15 mL of the Diluent Buffer |
| 25 ng/mL | 0.15 mL of the 50 ng/mL std. | 0.15 mL of the Diluent Buffer |
| 12.5 ng/mL | 0.15 mL of the 25 ng/mL std. | 0.15 mL of the Diluent Buffer |
| 6.25 ng/mL | 0.15 mL of the 12.5 ng/mL std. | 0.15 mL of the Diluent Buffer |
| 3.12 ng/mL | 0.15 mL of the 6.25 ng/mL std. | 0.15 mL of the Diluent Buffer |
| 1.6 ng/mL | 0.15 mL of the 3.12 ng/mL std. | 0.15 mL of the Diluent Buffer |
| 0 ng/mL | 0.15 mL of the Diluent Buffer | An empty tube |

B. Dilution of FAK (Total) Standard

Remaining reconstituted standard should be discarded or frozen in aliquots at -80°C for further use. Standard can be frozen and thawed one time only without loss of immunoreactivity.

C. Storage and Final Dilution of Anti-Rabbit IgG HRP (100X)

Please Note: The *Anti-Rabbit IgG HRP (100X)* is in 50% glycerol. This solution is viscous. To ensure accurate dilution, allow *Anti-Rabbit IgG HRP (100X)* to reach room temperature. Gently mix. Pipette *Anti-Rabbit IgG HRP (100X)* slowly. Remove excess concentrate solution from pipette tip by gently wiping with clean absorbent paper.

 Dilute 10 μL of this 100X concentrated solution with 1 mL of *HRP Diluent* for each 8-well strip used in the assay. Label as Anti-Rabbit IgG HRP Working Solution.

For Example:

| # of 8-Well Strips | Volume of Anti-Rabbit IgG HRP (100X) | Volume of Diluent |
|-----------------------|--|-------------------|
| 2 | 20 µL solution | 2 mL |
| 4 | 40 µL solution | 4 mL |
| 6 | 60 µL solution | 6 mL |
| 8 | 80 µL solution | 8 mL |
| 10 | 100 µL solution | 10 mL |
| 12 | 120 µL solution | 12 mL |

2. Return the unused Anti-Rabbit IgG HRP (100X) to the refrigerator.

D. Dilution of Wash Buffer

Allow the *Wash Buffer Concentrate (25X)* to reach room temperature and mix to ensure that any precipitated salts have redissolved. Dilute 1 volume of the *Wash Buffer Concentrate (25X)* with 24 volumes of deionized water (e.g., 50 mL may be diluted up to 1.25 liters, 100 mL may be diluted up to 2.5 liters). Label as Working Wash Buffer.

Store both the concentrate and the Working Wash Buffer in the refrigerator. The diluted buffer should be used within 14 days.

ASSAY METHOD: PROCEDURE AND CALCULATIONS

Be sure to read the *Procedural Notes/Lab Quality Control* section before carrying out the assay.

Allow all reagents to reach room temperature before use. Gently mix all liquid reagents prior to use.

Note: A standard curve must be run with each assay.

- 1. Determine the number of 8-well strips needed for the assay. Insert these in the frame(s) for current use. (Re-bag extra strips and frame. Store these in the refrigerator for future use.)
- 2. Add 50 µL of the *Standard Diluent Buffer* to zero wells. Well(s) reserved for chromogen blank should be left empty.
- 3. Add 50 μ L of standards and samples or controls to the appropriate microtiter wells. Tap gently on side of plate to mix.
- Pipette 50 μL FAK (Total) Detection Antibody solution into each well except the chromogen blank(s). Samples prepared in Cell Extraction Buffer must be diluted 1:5 or greater in Standard Diluent Buffer (for example, 10 μL sample into 40 μL buffer).

While a 1:5 sample dilution has been found to be satisfactory, higher dilutions such as 1:10 or 1:20 may be optimal. The dilution chosen should be optimized for each experimental system. Tap gently on the side of the plate to thoroughly mix. (See **REAGENT PREPARATION AND STORAGE**, Section B.)

- 5. Cover wells with *plate cover* and incubate for **3 hours at room temperature.**
- 6. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See **DIRECTIONS FOR WASHING**.
- Add 100 μL Anti-Rabbit IgG HRP Working Solution to each well except the chromogen blank(s). (Prepare the working dilution as described in **REAGENT PREPARATION AND STORAGE**, Section C.)
- 8. Cover wells with the *plate cover* and incubate for **30 minutes at room temperature**.
- 9. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See **DIRECTIONS FOR WASHING**.
- 10. Add 100 μ L of *Stabilized Chromogen* to each well. The liquid in the wells will begin to turn blue.
- 11. Incubate for **30 minutes at room temperature and in the dark**. *Please Note*: **Do not cover the plate with aluminum foil or metalized mylar**. The incubation time for chromogen substrate is often determined by the microtiter plate reader used. Many plate readers have the capacity to record a maximum optical density (O.D.) of 2.0. The O.D. values should be monitored and the substrate reaction stopped before the O.D. of the positive wells exceed the limits of the instrument. The O.D. values at 450 nm can

only be read after the *Stop Solution* has been added to each well. If using a reader that records only to 2.0 O.D., stopping the assay after 20 to 25 minutes is suggested.

- 12. Add 100 μ L of *Stop Solution* to each well. Tap side of plate gently to mix. The solution in the wells should change from blue to yellow.
- 13. Read the absorbance of each well at 450 nm having blanked the plate reader against a chromogen blank composed of 100 μ L each of *Stabilized Chromogen* and *Stop Solution*. Read the plate within 2 hours after adding the *Stop Solution*.
- 14. Plot the absorbance of the standards against the standard concentration. (Optimally, the background absorbance may be subtracted from *all* data points, including standards, unknowns and controls, prior to plotting.) Draw the best smooth curve through these points to construct the standard curve. If using curve fitting software, the four parameter algorithm provides the best curve fit.
- 15. Read the FAK (Total) concentrations for unknown samples and controls from the standard curve plotted in step 14. **Multiply value(s) obtained for sample(s) by the appropriate dilution factor to correct for the dilution with** *Standard Diluent Buffer*. (Samples producing signals higher than the highest standard (100 ng/mL) should be further diluted in *Standard Diluent Buffer* and reanalyzed, multiplying the concentration by the appropriate dilution factor.)

TYPICAL DATA

The following data were obtained for the various standards over the range of 0 to 100 ng/mL FAK (Total).

| Standard FAK (Total) (ng/mL) | Optical Density (450 nm) |
|---------------------------------|-----------------------------|
| 100 | 3.26 |
| 50 | 1.86 |
| 25 | 0.99 |
| 12.5 | 0.60 |
| 6.25 | 0.40 |
| 3.12 | 0.29 |
| 1.6 | 0.18 |
| 0 | 0.15 |

LIMITATIONS OF THE PROCEDURE

Do not extrapolate the standard curve beyond the 100 ng/mL standard point; the dose-response is non-linear in this region and accuracy is difficult to obtain. Dilute samples >100 ng/mL with *Standard Diluent Buffer*; reanalyze these and multiply results by the appropriate dilution factor.

The influence of various extraction buffers has not been thoroughly investigated. The rate of degradation of native FAK in various matrices has not been investigated. Although FAK degradation in the Cell Extraction Buffer described in this protocol has not been seen to date, the possibility of this occurrence cannot be excluded.

For Research Use Only. CAUTION: Not for human or animal therapeutic or diagnostic use.


PERFORMANCE CHARACTERISTICS

SENSITIVITY

The analytical sensitivity of this assay is <1.6 ng/mL of FAK. This was determined by adding two standard deviations to the mean O.D. obtained when the zero standard was assayed 16 times. Using 3T3L1 cells, this level of sensitivity was equivalent to the detection of FAK in 6000 cells.

The sensitivity of this ELISA was compared to Western blotting using known quantities of FAK. The data presented in Figure 1 show that the sensitivity of the ELISA is approximately 2x greater than that of Western blotting. The bands shown in the Western blotting data were developed using rabbit anti-FAK, and an alkaline phosphatase conjugated anti-rabbit IgG followed by chemiluminescent substrate and autoradiography.

Figure 1: Detection of FAK (Total) by ELISA vs Western Blot:



PRECISION

1. Intra-Assay Precision

Samples of known FAK concentration were assayed in replicates of 16 to determine precision within an assay.

| | Sample 1 | Sample 2 | Sample 3 |
|--------------|----------|----------|----------|
| Mean (ng/mL) | 47.2 | 24.9 | 10.1 |
| SD | 2.0 | 0.82 | 0.63 |
| %CV | 4.2 | 3.3 | 6.2 |

SD = Standard Deviation

CV = Coefficient of Variation

2. Inter-Assay Precision

Samples were assayed 48 times in multiple assays to determine precision between assays.

| | Sample 1 | Sample 2 | Sample 3 |
|--------------|----------|----------|----------|
| Mean (ng/mL) | 47.1 | 24.6 | 9.8 |
| SD | 2.4 | 1.7 | 0.99 |
| %CV | 5.1 | 6.9 | 10.1 |

SD = Standard Deviation

CV = Coefficient of Variation

RECOVERY


To evaluate recovery, FAK (Total) Standard was spiked at 3 different concentrations into 20% Cell Extraction Buffer. The average recovery was 101%.

HIGH DOSE HOOK EFFECT

Samples spiked with FAK (Total) Standard up to 400 ng/mL give responses higher than that obtained from the last standard point.

PARALLELISM

Natural FAK from 3T3L1 cell lysate was serially diluted in Standard Diluent Buffer. The optical density of each dilution was plotted against the FAK (Total) standard curve. Parallelism demonstrated by the figure below indicated that the standard accurately reflects FAK (Total) content in samples.





LINEARITY OF DILUTION

3T3L1 cells were grown in tissue culture medium containing 10% fetal calf serum and lysed with Cell Extraction Buffer. This lysate was diluted in *Standard Diluent Buffer* over the range of the assay and measured for FAK. Linear regression analysis of sample values versus the expected concentration yielded a correlation coefficient of 0.99.


| | Cell Lysate | | |
|----------|---------------------|---------------------|---------------|
| Dilution | Measured (ng/mL) | Expected (ng/mL) | % Expected |
| Neat | 34.56 | 34.56 | 100 |
| 1/2 | 17.13 | 17.28 | 100.8 |
| 1/4 | 8.44 | 8.64 | 102.4 |
| 1/8 | 4.17 | 4.32 | 103.6 |
| 1/16 | 2.53 | 2.16 | 85.4 |

SPECIFICITY

200 µg/mL of cell extracts form Jurkat, 3T3L1 and L6 cells were analyzed by FAK (Total) ELISA. The Invitrogen FAK (Total) ELISA recognizes human, rat, and mouse FAK (Figure 3). Other species have not been tested.


The FAK (Total) ELISA kit is specific for measurement of total FAK protein. The following proteins were tested in the assay and found to have no cross-reactivity: p38 MAPK, AKT, EGFR, GSK 3beta, JNK, HSP27, Paxillin, and SRC.

Figure 3




In Figure 4 and Figure 5, 3T3L1 cells were treated with 1 mM sodium orthovanadate for 5 hours and untreated 3T3L1 cells were used as control. Cell extracts were prepared in 0.1% SDS extraction buffer. 50 μ L of each cell lysate (400 μ g/mL) was analyzed with FAK (Total) ELISA and Invitrogen's FAK [pY397] ELISA (Cat. # KHO0441). The FAK [pY397] detected phosphorylated FAK recombinant protein and phosphorylated FAK in orthovanadate-treated 3T3L1 cells, but not the non-phosphorylated FAK recombinant protein or non-phosphorylated FAK in untreated 3T3L1 cells (Figure 4). In contrast, FAK (Total) ELISA kit detected both phosphorylated and non-phosphorylated FAK recombinant protein and phosphorylated FAK in orthovanadate-treated cells and untreated control (Figure 5).

Figure 4







This "Total" assay is designed to allow normalization of FAK content among samples to permit interpretation of results from the phosphorylation site-specific FAK [pY397] ELISA kit available from Invitrogen (Cat. # KHO0441).

REFERENCES

- 1. Crowe, D.L., et al. (2004) Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation. BMC Cancer 4:18.
- Cary, L.A., et al. (1996) Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J. Cell. Sci. 109:1787-1794.
- 3. Igishi, T., et al. (1999) Divergent signaling pathways link focal adhesion kinase to mitogen-activated protein kinase cascades. Evidence for a role of paxillin in c-Jun NH(2)-terminal kinase activation. J. Biol. Chem. 274:30738-30746.
- Jones, G., et al. (2001) Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res. 61:4978-4981.
- Lee, J.W., et al. (2003) The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines. J. Orthop. Res. 21:1071-1080.
- Owen, J.D., et al. (1999) Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol. Cell. Biol. 19:4806-4818.

- Ruest, P.J., et al. (2000) Phosphospecific antibodies reveal focal adhesion kinase activation loop phosphorylation in nascent and mature focal adhesions and requirement for the autophosphorylation site. Cell Growth Differ. 11:41-48.
- Sieg, D.J., et al. (1999) Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J. Cell Sci. 112:2677-2691.
- Streblow, D.N., et al. (2003) Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J. Biol. Chem. 278:50456-50465.
- Xu, L.H., et al. (2004) The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. J. Biol. Chem. 275:30597-30604.
- 11. Yu, H.G., et al. (2004) Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells. Biochem. Pharmacol. 67:135-146.

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

| Symbol | Description | Symbol | Description |
|------------|---|-------------|--|
| REF | Catalogue Number | LOT | Batch code |
| RUO | Research Use Only | IVD | In vitro diagnostic medical device |
| X | Use by | ł | Temperature limitation |
| *** | Manufacturer | EC REP | European Community authorised representative |
| [-] | Without, does not contain | [+] | With, contains |
| from Light | Protect from light | \triangle | Consult accompanying documents |
| []i | Directs the user to consult instructions for use (IFU), accompanying the product. | | |

Explanation of symbols

Notes

FAK (Total) Assay Summary

